Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.32 |
| ▸ | TAOK3 | Q9H2K8 | 3/20 | 0.31 |
| ▸ | TAOK1 | Q7L7X3 | 2/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19227891 | 0.92 | MTNR1A (0.32) | MTNR1AMTNR1BTAOK3TAOK1 | |
| SCHEMBL18797989 | 0.91 | MTNR1A (0.32) | MTNR1AMTNR1BDRD2GRM5 | |
| SCHEMBL22667424 | 0.89 | MTNR1A (0.34) | MTNR1AMTNR1BTAOK3TAOK1 | |
| SCHEMBL23129944 | 0.88 | MTNR1A (0.31) | MTNR1AMTNR1BTAOK3TAOK1 | |
| SCHEMBL22667460 | 0.88 | SMN1; SMN2 (0.31) | MTNR1AMTNR1BTAOK3TAOK1 | |
| SCHEMBL18797990 | 0.88 | MTNR1A (0.32) | MTNR1AMTNR1BDRD2GRM5 | |
| SCHEMBL18797987 | 0.86 | — | — | |
| SCHEMBL19228022 | 0.86 | TAOK3 (0.33) | TAOK3TAOK1 | |
| SCHEMBL18797988 | 0.85 | — | — | |
| SCHEMBL19662964 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9783555-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20170226135-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-08-10 | — | — | US | disclosed |
| US-9637504-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2017-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226135-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | MTNR1A 3641/4885MTNR1B 3337/4885TAOK3 3597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.